Skip to content
Open access

Targeting the E3 ubiquitin ligase RNF10 ameliorates metabolic dysfunction–associated steatohepatitis in mice

Aug 2026 · Journal of Clinical Investigation · Vol 136 · 0 citations · 63 references
Medicine

TL;DR

It is shown that E3 ubiquitin ligase RING finger protein 10 (RNF10) protein levels were positively correlated with MASLD in both mice and humans and interfering with the expression or function of RNF10 may be a promising therapeutic strategy for MASLD.

Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as a global health concern. Nevertheless, its underlying pathological mechanisms remain poorly understood. Here, we showed that E3 ubiquitin ligase RING finger protein 10 (RNF10) protein levels were positively correlated with MASLD in both mice and humans. Hepatocyte-specific Rnf10 deletion attenuated liver steatosis, inflammation, and fibrosis. Conversely, adeno-associated virus–mediated hepatocyte-specific Rnf10 overexpression exacerbated MASLD-related phenotypes. Mechanistically, RNF10 interacted with carnitine palmitoyltransferase 1A and facilitated its degradation through K48-linked ubiquitination, thereby inhibiting fatty acid oxidation, promoting hepatic lipid accumulation, and ultimately exacerbating liver inflammation and fibrosis. Moreover, we utilized triantennary N-acetylgalactosamine to deliver siRNA specifically targeting Rnf10 to hepatocytes. This approach effectively ameliorated diet-induced liver steatosis, inflammation, and fibrosis in mice. Therefore, interfering with the expression or function of RNF10 may be a promising therapeutic strategy for MASLD.

Read PDF

Similar papers

Open access Sep 2026

Ovarian tumor domain-containing protein 1 deficiency attenuates metabolic dysfunction-associated steatotic liver disease by promoting the ubiquitination of HSP90α in hepatocytes

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, yet approved pharmacotherapies remain limited. The ovarian tumor domain-containing protein 1 (OTUD1) has been implicated in metabolic regulation, but its role in MASLD remains unclear. OTUD1 expressio...

Mei-Qin Huang, Si-Yi Wei, Meng-Zhen-Yuan-Hua Li et al. · 0 citations
Open access Sep 2026

Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood. METHODS We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core...

Yan Wang, Shuang-Shuang Lu · 0 citations
Sep 2026

Sinusoidal endothelial cells orchestrate liver inflammation and lipid metabolism via USP12/CD36 axis being the target of celastrol therapy.

Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly amel...

Hu Hua, Wen-Ping Zhu, Le-Hang Sun et al. · 0 citations
Open access Sep 2026

Limited impact of NLRP3 inflammasome deficiency on diet-induced metabolic dysfunction-associated steatohepatitis in mice

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and a growing cause of chronic liver disease worldwide. Although the NLRP3 inflammasome has been implicated in MASH pathogenesis, its contribution remains controversial acros...

Daisuke Taguchi, Y. Shirakami, Toshihide Maeda et al. · 0 citations
Open access Aug 2026

Deletion of protein tyrosine phosphatase 1B in hepatocytes attenuates inflammation, steatosis, and fibrosis in a dietary mouse model of metabolic dysfunction-associated steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver-related morbidity and mortality. The current interventions are limited, underscoring the need for novel mechanism-based therapies. Protein tyrosine phosphatase 1B (PTP1B) regulates phosphotyrosine signaling and hepatic metabolism,...

Ming-Fo Hsu, Yoshihiro Ito, Ulrik N. Mjaaseth et al. · 0 citations
Open access Sep 2026

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models.

Metabolic dysfunction-associated steatohepatitis (MASH) is rising globally despite recent therapeutic advances, highlighting the need to identify new targetable pathways. While dysregulated lipid and amino acid metabolism are established features of MASH, the interplay between these two metabolic pathways remains unexp...

S. Anand, Sandeep Das, Fabio Arias et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.